Why is the CSL share price on the slide today?

Shares in the ASX healthcare giant are holding their own on Tuesday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The ASX 200 is in the green so far this Tuesday
  • Not so the CSL share price although, curiously, it's holding up rather well
  • That's despite CSL shares trading ex-dividend today

It's been a wavering start to the trading day for the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. At the time of writing, the ASX 200 has gained just 0.09% and is back below 6,860 points. But it's still ahead of the CSL Limited (ASX: CSL) share price.

CSL shares are down 0.1% at the time of writing. The ASX 200 healthcare giant closed at $294.80 a share yesterday. It opened at $294.42 this morning and is now trading at $294.50 at the time of writing.

This doesn't exactly appear to be a strong session for CSL shares, given the ASX 200 is slightly outperforming these gains so far. But it is if we factor in what has just happened to the CSL share price. The company has just traded ex-dividend today for the upcoming final dividend payment for FY22.

When CSL revealed its full-year earnings report for FY22 last month, it declared a final dividend of US$1.18 per share. That translates to $1.68 per share, partially franked at 10%.

As we discussed yesterday, this was flat in US dollar terms on last year's final dividend. But thanks to favourable currency exchange rates, ASX investors will enjoy a 5.6% boost from what they received last year.

The dividend is scheduled to be paid out next month on 5 October, so investors will have to wait until then to see the cash.

A scientist examining test results.

Image source: Getty Images

CSL share price rises, despite ex-dividend date

But CSL shares traded ex-dividend for this upcoming final payment today. That means that any new investors in CSL from today are not eligible to receive this dividend.

Normally, when a company trades ex-dividend, we see a corresponding drop in the company's share price. This reflects the reality that CSL shares are less valuable, thanks to the fact that the dividend is no longer available for new investors.

Today, we have seen no such obvious drop. That means that CSL is having a fairly strong day – if it weren't for the ex-dividend date, the company would probably be enjoying gains.

So arguably, this is a very happy day for CSL investors.

At the current CSL share price, this ASX 200 healthcare share has a dividend yield of 1.02%.

Motley Fool contributor Sebastian Bowen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »